Data from: Ameliorative effect of roxithromycin against prostate inflammation-induced chronic pelvic pain in a preclinical model

In view of the well-known anti-inflammatory property of roxithromycin, the
present study was carried out to evaluate its efficacy in ameliorating
prostate inflammation-induced chronic pelvic pain in a rat model.
Inflammation was induced by a single intra-prostatic injection of
carrageenan, where a time course study revealed a peak histology score on
day 14. The efficacy study was carried out in four sets of rats, each
comprising 5 groups, which included the respective normal and experimental
controls (NC, EC). The drugs (roxithromycin 5 and 20 mg/kg, diclofenac 5
mg/kg) were given daily orally, and pain score and body weight were
evaluated at different time intervals. The prostatic index, vascular
permeability, tissue levels of TNF-α and PGE2, thiobarbituric
acid reactive substances, glutathione and superoxide dismutase, histology
score, and immunoreactivity of COX-2 and iNOS were evaluated on day 14.
Like diclofenac, roxithromycin decreased pain scores, and the rats gained
weight during the study period as compared to the EC group. The beneficial
effect of roxithromycin was also evident from the dose-dependent
restoration of markers of inflammation and oxidative stress.This study
shows that by alleviating pain and suppressing inflammation and oxidative
stress,roxithromycin has a potential to provide relief in prostatitis.